Glucose Metabolism Disorders  >>  Synjardy (empagliflozin/metformin)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Synjardy (empagliflozin/metformin) / Boehringer Ingelheim, Eli Lilly
NCT01368081: Empagliflozin (BI 10773) Comprehensive add-on Study in Japanese Subjects With Type 2 Diabetes Mellitus

Completed
3
1162
Japan
Metformin, BI 10773, Placebo (low dose), Placebo (high dose)
Boehringer Ingelheim, Eli Lilly and Company
Diabetes Mellitus, Type 2
04/13
04/13
NCT01167881 / 2009-016244-39: Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes

Completed
3
1549
US, Canada, Europe, RoW
BI 10773, Glimepiride, Placebo
Boehringer Ingelheim, Eli Lilly and Company
Diabetes Mellitus, Type 2
08/13
08/15
NCT01719003 / 2010-021375-92: Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes

Completed
3
1413
US, Canada, Europe, RoW
Metformin 500 mg bid, Metformin 1000 mg bid, Empagliflozin low dose qd, Empagliflozin high dose qd, Empagliflozin low dose bid, Empagliflozin high dose bid
Boehringer Ingelheim, Eli Lilly and Company
Diabetes Mellitus, Type 2, Hyperglycemia
11/14
12/14

Download Options